Nelia HernÃ;ndez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/868979/publications.pdf

Version: 2024-02-01

567281 501196 28 839 15 28 citations h-index g-index papers 32 32 32 1130 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology, 2014, 147, 109-118.e5.	1.3	248
2	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Annals of Hepatology, 2020, 19, 674-690.	1.5	72
3	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. International Journal of Molecular Sciences, 2016, 17, 313.	4.1	63
4	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver International, 2018, 38, 136-143.	3.9	58
5	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology, 2020, 18, 2554-2563.e3.	4.4	48
6	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroidâ€responsive hepatitis: report of 22 cases. Liver International, 2016, 36, 302-310.	3.9	39
7	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterology Journal, 2019, 7, 825-837.	3.8	29
8	Impact of Public Health Policies on Alcoholâ€Associated Liver Disease in Latin America: An Ecological Multinational Study. Hepatology, 2021, 74, 2478-2490.	7.3	27
9	Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety, 2016, 15, 1463-1475.	2.4	26
10	Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America. Clinical Gastroenterology and Hepatology, 2017, 15, 1631-1632.	4.4	22
11	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clinical Liver Disease, 2019, 13, 51-57.	2.1	21
12	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563.	4.4	21
13	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Seminars in Liver Disease, 2019, 39, 381-394.	3.6	20
14	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Annals of Hepatology, 2021, 24, 100321.	1.5	19
15	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 2018, 16, 292-294.	4.4	18
16	IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virology Journal, 2018, 15, 40.	3.4	14
17	Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries. Virus Research, 2016, 223, 140-146.	2.2	13
18	Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCVâ€infected patients in realâ€ife cohort from Latin America. Journal of Medical Virology, 2017, 89, 1590-1596.	a _{5.0}	13

#	Article	IF	CITATIONS
19	Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Disease Markers, 2018, 2018, 1-9.	1.3	11
20	The influence of drug properties and host factors on delayed onset of symptoms in drugâ€induced liver injury. Liver International, 2018, 39, 401-410.	3.9	10
21	Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics. Seminars in Liver Disease, 2021, 41, 331-348.	3.6	9
22	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Annals of Hepatology, 2014, 13, 231-9.	1.5	9
23	Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.	4.2	7
24	Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Realâ€world experience from HCV‣ALREAN cohort. Journal of Medical Virology, 2020, 92, 3545-3555.	5.0	4
25	Translating new knowledge on drug-induced liver injury into clinical practice. Frontline Gastroenterology, 2020, 11, 303-310.	1.8	4
26	Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report. BMC Infectious Diseases, 2021, 21, 387.	2.9	4
27	Hepatotoxicity of New Antitumor Agents. Current Hepatology Reports, 2017, 16, 293-297.	0.9	2
28	Response to: Comment on "Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients― Disease Markers, 2019, 2019, 1-4.	1.3	0